Economic burden of patients with leading cancers in China: a cost-of-illness study.
Cancer costs
China
Cost-of-illness
Treatment phases
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
28
06
2024
accepted:
30
08
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. Comprehensive analyses of the economic burden on patients across different cancer treatment phases, based on empirical data, are lacking. This study aims to estimate the financial burden borne by patients and analyze the cost compositions of the leading cancers with the highest number of new cases in China. This cross-sectional cost-of-illness study analyzed patients diagnosed with lung, breast, colorectal, esophageal, liver, or gastric cancer, identified through electronic health records (EHRs) from 84 hospitals across 17 provinces in China. Patients completed any one of the initial treatment phase, follow-up phase, and relapse/metastasis phase were recruited by trained attending physicians through a stratified sampling procedure to ensure enough cases for each cancer progression stage and cancer treatment phase. Direct and indirect costs by treatment phase were collected from the EHRs and self-reported surveys. We estimated per case cost for each type of cancer, and employed subgroup analyses and multiple linear regression models to explore cost drivers. We recruited a total of 13,745 cancer patients across three treatment phases. The relapse/metastasis phase incurred the highest per case costs, varying from $8,890 to $14,572, while the follow-up phase was the least costly, ranging from $1,840 to $4,431. Being in the relapse/metastasis phase and having an advanced clinical stage of cancer at diagnosis were associated with significantly higher cost, while patients with low socioeconomic status borne lower costs. There were substantial financial burden on patients with six leading cancers in China. Health policymakers should emphasize comprehensive healthcare coverage for marginalized populations such as the uninsured, less educated, and those living in underdeveloped regions.
Sections du résumé
BACKGROUND
BACKGROUND
China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. Comprehensive analyses of the economic burden on patients across different cancer treatment phases, based on empirical data, are lacking. This study aims to estimate the financial burden borne by patients and analyze the cost compositions of the leading cancers with the highest number of new cases in China.
METHODS
METHODS
This cross-sectional cost-of-illness study analyzed patients diagnosed with lung, breast, colorectal, esophageal, liver, or gastric cancer, identified through electronic health records (EHRs) from 84 hospitals across 17 provinces in China. Patients completed any one of the initial treatment phase, follow-up phase, and relapse/metastasis phase were recruited by trained attending physicians through a stratified sampling procedure to ensure enough cases for each cancer progression stage and cancer treatment phase. Direct and indirect costs by treatment phase were collected from the EHRs and self-reported surveys. We estimated per case cost for each type of cancer, and employed subgroup analyses and multiple linear regression models to explore cost drivers.
RESULTS
RESULTS
We recruited a total of 13,745 cancer patients across three treatment phases. The relapse/metastasis phase incurred the highest per case costs, varying from $8,890 to $14,572, while the follow-up phase was the least costly, ranging from $1,840 to $4,431. Being in the relapse/metastasis phase and having an advanced clinical stage of cancer at diagnosis were associated with significantly higher cost, while patients with low socioeconomic status borne lower costs.
CONCLUSIONS
CONCLUSIONS
There were substantial financial burden on patients with six leading cancers in China. Health policymakers should emphasize comprehensive healthcare coverage for marginalized populations such as the uninsured, less educated, and those living in underdeveloped regions.
Identifiants
pubmed: 39334309
doi: 10.1186/s12913-024-11514-x
pii: 10.1186/s12913-024-11514-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1135Subventions
Organisme : China National Cancer Center
ID : NA
Informations de copyright
© 2024. The Author(s).
Références
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.
doi: 10.1016/S0140-6736(20)30925-9
Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–91.
doi: 10.1097/CM9.0000000000001474
pubmed: 33734139
Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health. 2023;8(12):e943–55.
doi: 10.1016/S2468-2667(23)00211-6
pubmed: 38000889
Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153–65.
doi: 10.3322/caac.21443
pubmed: 29338071
pmcid: 6652174
Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L et al. Estimates and projections of the Global Economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023.
Uppal N, Cunningham Nee Lubitz C, James B. The cost and financial burden of thyroid Cancer on patients in the US: a review and directions for Future Research. JAMA Otolaryngol Head Neck Surg. 2022;148(6):568–75.
doi: 10.1001/jamaoto.2022.0660
pubmed: 35511135
Bhimani N, Wong GYM, Molloy C, Pavlakis N, Diakos CI, Clarke SJ, et al. Cost of treating metastatic colorectal cancer: a systematic review. Public Health. 2022;211:97–104.
doi: 10.1016/j.puhe.2022.06.022
pubmed: 36063775
Yousefi M, Jalilian H, Heydari S, Seyednejad F, Mir N. Cost of Lung Cancer: a systematic review. Value Health Reg Issues. 2023;33:17–26.
doi: 10.1016/j.vhri.2022.07.007
pubmed: 36201970
Guo LW, Huang HY, Shi JF, Lv LH, Bai YN, Mao AY, et al. Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002–2011). Chin J Cancer. 2017;36(1):73.
doi: 10.1186/s40880-017-0242-3
pubmed: 28882179
pmcid: 5590174
Qiu WQ, Shi JF, Guo LW, Mao AY, Huang HY, Hu GY, et al. Medical expenditure for liver cancer in urban China: a 10-year multicenter retrospective survey (2002–2011). J Cancer Res Ther. 2018;14(1):163–70.
doi: 10.4103/jcrt.JCRT_709_16
pubmed: 29516981
Shi JF, Wang L, Ran JC, Wang H, Liu CC, Zhang HZ, et al. Clinical characteristics, medical service utilization, and expenditure for colorectal cancer in China, 2005 to 2014: overall design and results from a multicenter retrospective epidemiologic survey. Cancer. 2021;127(11):1880–93.
doi: 10.1002/cncr.33445
pubmed: 33784413
Shi JF, Wang L, Wu N, Li JL, Hui ZG, Liu SM, et al. Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer. 2019;128:91–100.
doi: 10.1016/j.lungcan.2018.11.031
pubmed: 30642458
Sun CY, Shi JF, Fu WQ, Zhang X, Liu GX, Chen WQ, et al. Catastrophic Health expenditure and its determinants among households with breast Cancer patients in China: a Multicentre, cross-sectional survey. Front Public Health. 2021;9:704700.
doi: 10.3389/fpubh.2021.704700
pubmed: 34291034
pmcid: 8287064
Ma L, Chen XZ, Liu YQ, Hu XB, Gong HX. The direct economic burden analysis for four common cancer in elderly in Lanzhou city of China. Chin J Gerontol. 2011;31(17):3352–4.
Bhimani N, Wong GY, Molloy C, Dieng M, Hugh TJ. Cost of colorectal cancer by treatment type from different health economic perspectives: a systematic review. Eur J Surg Oncol. 2022;48(10):2082–93.
doi: 10.1016/j.ejso.2022.06.023
pubmed: 35787341
Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2006–14.
doi: 10.1158/1055-9965.EPI-11-0650
pubmed: 21980008
pmcid: 3191884
Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630–41.
doi: 10.1093/jnci/djn103
pubmed: 18445825
Liu C, Shi J, Wang H, Yan X, Wang L, Ren J, et al. Population-level economic burden of lung cancer in China: Provisional prevalence-based estimations, 2017–2030. Chin J Cancer Res. 2021;33(1):79–92.
doi: 10.21147/j.issn.1000-9604.2021.01.09
pubmed: 33707931
pmcid: 7941692
Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L et al. Global Cancer Observatory: Cancer Today: International Agency for Research on Cancer; 2020 [ https://gco.iarc.fr/today/en
Tuberculosis patient cost. Surveys: a handbook. Geneva: World Health Organization; 2017.
Olsson TM. Comparing top-down and bottom-up costing approaches for economic evaluation within social welfare. Eur J Health Econ. 2011;12(5):445–53.
doi: 10.1007/s10198-010-0257-z
pubmed: 20496157
Hanly P, Timmons A, Walsh PM, Sharp L. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health. 2012;15(3):429–36.
doi: 10.1016/j.jval.2011.12.012
pubmed: 22583452
Hanly P, Ortega-Ortega M, Soerjomataram I. Cancer premature mortality costs in Europe in 2020: a comparison of the Human Capital Approach and the Friction cost Approach. Curr Oncol. 2022;29(5):3552–64.
doi: 10.3390/curroncol29050287
pubmed: 35621677
pmcid: 9139545
Black N. The Cooksey review of UK health research funding. BMJ. 2006;333(7581):1231–2.
doi: 10.1136/bmj.39059.444120.80
pubmed: 17170394
pmcid: 1702444
Internal Revenue Service. Yearly Average Currency Exchange Rates 2023 [ https://www.irs.gov/individuals/international-taxpayers/yearly-average-currency-exchange-rates
Zhu K, Zhang L, Yuan S, Zhang X, Zhang Z. Health financing and integration of urban and rural residents’ basic medical insurance systems in China. Int J Equity Health. 2017;16(1):194.
doi: 10.1186/s12939-017-0690-z
pubmed: 29115955
pmcid: 5678764
Huang SY, Chen HM, Liao KH, Ko BS, Hsiao FY. Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017. BMJ Open. 2020;10(10):e036341.
doi: 10.1136/bmjopen-2019-036341
pubmed: 33039986
pmcid: 7549455
Park T, Hwang M. Health care use and expenditures attributable to cancer: a population-based study. Res Social Adm Pharm. 2021;17(7):1300–5.
doi: 10.1016/j.sapharm.2020.09.017
pubmed: 33054991
Jabbari A, Hadian M, Mazaheri E, Jelodar ZK. The economic cost of cancer treatment in Iran. J Educ Health Promot. 2023;12:32.
doi: 10.4103/jehp.jehp_928_21
pubmed: 37034875
pmcid: 10079181
Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888–97.
doi: 10.1093/jnci/djn175
pubmed: 18544740
pmcid: 3298963
Tramontano AC, Chen Y, Watson TR, Eckel A, Hur C, Kong CY. Esophageal cancer treatment costs by phase of care and treatment modality, 2000–2013. Cancer Med. 2019;8(11):5158–72.
doi: 10.1002/cam4.2451
pubmed: 31347306
pmcid: 6718574
Sorensen SV, Goh JW, Pan F, Chen C, Yardley D, Martin M, et al. Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int J Technol Assess Health Care. 2012;28(1):12–21.
doi: 10.1017/S026646231100064X
pubmed: 22617734
Hackl F, Halla M, Hummer M, Pruckner GJ. The effectiveness of Health Screening. Health Econ. 2015;24:913–35.
doi: 10.1002/hec.3072
pubmed: 25044494
Wilkinson AN, Seely JM, Rushton M, Williams P, Cordeiro E, Allard-Coutu A, et al. Capturing the true cost of breast Cancer Treatment: Molecular Subtype and Stage-specific per-case activity-based costing. Curr Oncol. 2023;30(9):7860–73.
doi: 10.3390/curroncol30090571
pubmed: 37754486
pmcid: 10527628
Zeng H, Ran X, An L, Zheng R, Zhang S, Ji JS, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. Lancet Public Health. 2021;6(12):e877–87.
doi: 10.1016/S2468-2667(21)00157-2
pubmed: 34838194
Acharya S, Ghimire S, Jeffers EM, Shrestha N. Health Care utilization and Health Care expenditure of Nepali older adults. Front Public Health. 2019;7:24.
doi: 10.3389/fpubh.2019.00024
pubmed: 30828573
pmcid: 6384236